<?xml version="1.0" encoding="UTF-8"?>
<search_results count="1048">
  <query>cannabis</query>
  <!-- Additional study fields may be added over time -->
  <study rank="1">
    <nct_id>NCT03614637</nct_id>
    <title>Cannabis Use and Epigenetic Alterations in Human Male Sperm Cells</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cannabis Use</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Cannabis use abstinence for 11 weeks</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Group differences in sperm DNA methylation profiles between user and non-user group</outcome_measure>
      <outcome_measure>Within group change in DNA methylation profiles from baseline to after 11 weeks of Cannabis abstinence</outcome_measure>
      <outcome_measure>Group differences in the sperm analysis profile between user and non-user group</outcome_measure>
      <outcome_measure>Within group change in sperm analysis profile from baseline to after eleven weeks of Cannabis abstinence</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Duke University</lead_sponsor>
      <collaborator>John Templeton Foundation</collaborator>
    </sponsors>
    <gender>Male</gender>
    <min_age>18 Years</min_age>
    <max_age>40 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>42</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>Pro00086400</other_id>
    </other_ids>
    <start_date>November 7, 2017</start_date>
    <primary_completion_date>March 16, 2020</primary_completion_date>
    <completion_date>March 16, 2020</completion_date>
    <study_first_posted>August 3, 2018</study_first_posted>
    <last_update_posted>July 7, 2020</last_update_posted>
    <locations>
      <location>Duke Child and Family Study Center, Durham, North Carolina, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03614637</url>
  </study>
  <study rank="2">
    <nct_id>NCT03994926</nct_id>
    <title>Evaluation of an Eye Tracking Sensor to Detect Cannabis Impairment</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cannabis Intoxication</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Virtual Reality Eye Tracking after smoking Cannabis - HTC Vive Pro-Eye</intervention>
      <intervention type="Drug">Cannabis cigarette - 4.0% THC</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change from baseline in Pupil Dilation</outcome_measure>
      <outcome_measure>Change from baseline in Gaze Nystagmus</outcome_measure>
      <outcome_measure>Change from baseline in Lack of Convergence</outcome_measure>
      <outcome_measure>Plasma THC</outcome_measure>
      <outcome_measure>Change from baseline in Cannabis Subjective Effects</outcome_measure>
      <outcome_measure>Change from baseline in Four Choice Reaction Time Task</outcome_measure>
      <outcome_measure>Change from baseline in Digit Symbol Substitution Task</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Battelle Memorial Institute</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Early Phase 1</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: N/A</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Device Feasibility</study_design>
    </study_designs>
    <other_ids>
      <other_id>131310</other_id>
    </other_ids>
    <start_date>February 3, 2020</start_date>
    <primary_completion_date>May 31, 2020</primary_completion_date>
    <completion_date>July 15, 2020</completion_date>
    <study_first_posted>June 21, 2019</study_first_posted>
    <last_update_posted>February 19, 2020</last_update_posted>
    <locations>
      <location>Battelle Memorial Institute, Baltimore, Maryland, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03994926</url>
  </study>
  <study rank="3">
    <nct_id>NCT04106336</nct_id>
    <title>Cortical Excitability and Role of rTMS in Cannabis Use Disorder</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cannabis Use Disorder, Moderate</condition>
    </conditions>
    <interventions>
      <intervention type="Device">rTMS</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Determination of role of rTMS for reducing cannabis craving</outcome_measure>
      <outcome_measure>Estimation of cortical excitability in cannabis addict</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assiut University</lead_sponsor>
    </sponsors>
    <gender>Male</gender>
    <min_age>18 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Early Phase 1</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>rTMS in cannabis use disorder</other_id>
    </other_ids>
    <start_date>October 1, 2019</start_date>
    <primary_completion_date>October 1, 2020</primary_completion_date>
    <completion_date>December 30, 2020</completion_date>
    <study_first_posted>September 27, 2019</study_first_posted>
    <last_update_posted>September 27, 2019</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04106336</url>
  </study>
  <study rank="4">
    <nct_id>NCT03813602</nct_id>
    <title>Detection of Cannabis Impairment With an Eye Tracker</title>
    <acronym>ACS</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cannabis Intoxication</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Cannabis Sativa</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in eye gaze</outcome_measure>
      <outcome_measure>Change in saccades</outcome_measure>
      <outcome_measure>Change in eye fixations</outcome_measure>
      <outcome_measure>Change in blinking rate</outcome_measure>
      <outcome_measure>Change in blinking duration</outcome_measure>
      <outcome_measure>Change in blinking speed</outcome_measure>
      <outcome_measure>Change in pupil size</outcome_measure>
      <outcome_measure>Change in mean speed on the driving simulator</outcome_measure>
      <outcome_measure>Change in standard deviation of speed on the driving simulator</outcome_measure>
      <outcome_measure>Change in maximum speed on the driving simulator</outcome_measure>
      <outcome_measure>Change in standard deviation of lateral position on the driving simulator</outcome_measure>
      <outcome_measure>Change in minimum time to collision on the driving simulator</outcome_measure>
      <outcome_measure>Change in number of collisions</outcome_measure>
      <outcome_measure>Change in blood concentrations of delta-9-tetrahydrocannabinol</outcome_measure>
      <outcome_measure>Change in blood concentrations of carboxy-tetrahydrocannabinol</outcome_measure>
      <outcome_measure>Change in blood concentrations of 11-hydroxy-tetrahydrocannabinol</outcome_measure>
      <outcome_measure>Change in saliva THC detection</outcome_measure>
      <outcome_measure>Change in systolic blood pressure</outcome_measure>
      <outcome_measure>Change in diastolic blood pressure</outcome_measure>
      <outcome_measure>Change in heart rate</outcome_measure>
      <outcome_measure>Change in temperature</outcome_measure>
      <outcome_measure>Change in number of respirations per minute</outcome_measure>
      <outcome_measure>Change in Subjective cannabis effects with a visual analog scale</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre for Addiction and Mental Health</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>19 Years</min_age>
    <max_age>26 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: N/A</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Screening</study_design>
    </study_designs>
    <other_ids>
      <other_id>076/2018</other_id>
    </other_ids>
    <start_date>August 15, 2019</start_date>
    <primary_completion_date>November 15, 2019</primary_completion_date>
    <completion_date>November 15, 2019</completion_date>
    <study_first_posted>January 23, 2019</study_first_posted>
    <last_update_posted>December 12, 2019</last_update_posted>
    <locations>
      <location>Center for Addiction and Mental Health, Toronto, Ontario, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03813602</url>
  </study>
  <study rank="5">
    <nct_id>NCT03581058</nct_id>
    <title>Neural Correlates of Driving and Cannabis</title>
    <acronym/>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cannabis Use</condition>
      <condition>Driving Impaired</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Cannabis</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in neural activation on fMRI during driving simulation</outcome_measure>
      <outcome_measure>Performance on driving simulator</outcome_measure>
      <outcome_measure>Performance on cognitive tasks</outcome_measure>
      <outcome_measure>Blood plasma concentration levels of cannabinoids</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>St. Michael's Hospital, Toronto</lead_sponsor>
      <collaborator>University Health Network, Toronto</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>25 Years</min_age>
    <max_age>59 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <other_ids>
      <other_id>17-206</other_id>
    </other_ids>
    <start_date>August 8, 2018</start_date>
    <primary_completion_date>December 31, 2020</primary_completion_date>
    <completion_date>December 31, 2020</completion_date>
    <study_first_posted>July 10, 2018</study_first_posted>
    <last_update_posted>March 23, 2020</last_update_posted>
    <locations>
      <location>University Health Network, Toronto, Ontario, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03581058</url>
  </study>
  <study rank="6">
    <nct_id>NCT04517474</nct_id>
    <title>Comparing the Spanish Version of CANreduce With or Without Psychological Support and Treatment as Usual, Reducing Cannabis Use.</title>
    <acronym>CANREDUCE</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cannabis Use Disorder</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">CANreduce</intervention>
      <intervention type="Behavioral">psychological support</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in the number of days of self-reported cannabis use in the past 30 days (TLFB)</outcome_measure>
      <outcome_measure>Change in the number of days of weekly self-reported cannabis use Time Life Follow Back (TLFB)</outcome_measure>
      <outcome_measure>Change in the quantity of weekly standard joints (TLFB with predifined cannabis standard joints)</outcome_measure>
      <outcome_measure>Change in the scoring of the Cannabis Use Disorder Identification Test - Revised (CUDIT-R)</outcome_measure>
      <outcome_measure>Change in the scoring of the Severity Dependence Scale (SDS)</outcome_measure>
      <outcome_measure>Change in the scoring of the Alcohol Use Disorders Identification Test (AUDIT)</outcome_measure>
      <outcome_measure>Change in the scoring of the PROMIS Emotional Distress - Depression - Short Form 8b</outcome_measure>
      <outcome_measure>Change in the scoring of the PROMIS Anxiety 8a - Adult v1.0</outcome_measure>
      <outcome_measure>Change in the scoring of the EQ-5D-5L</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Parc de Salut Mar</lead_sponsor>
      <collaborator>Swiss Research Institute for Public Health and Addiction (ISGF)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>2019/8901/I</other_id>
    </other_ids>
    <start_date>September 10, 2020</start_date>
    <primary_completion_date>April 1, 2022</primary_completion_date>
    <completion_date>November 1, 2022</completion_date>
    <study_first_posted>August 18, 2020</study_first_posted>
    <last_update_posted>August 18, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04517474</url>
  </study>
  <study rank="7">
    <nct_id>NCT02849587</nct_id>
    <title>Using a Field Performance Test on an iPad to Evaluate Driving Under the Influence of Cannabis</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cannabis Intoxication</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">cannabis</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Driving Simulation Global Driving Deficit Score (GDDS)</outcome_measure>
      <outcome_measure>Driving Simulation Measuring Deviation of Lateral Position</outcome_measure>
      <outcome_measure>Driving Simulation Measuring Speed Deviation</outcome_measure>
      <outcome_measure>Driving Simulation Measuring Divided Attention</outcome_measure>
      <outcome_measure>Driving Simulation Measuring Car Following - Coherence</outcome_measure>
      <outcome_measure>5. Driving Simulation Measuring Car Following - reaction time to changes in the lead car's speed.</outcome_measure>
      <outcome_measure>Driving Simulation Measuring Car Following - distance from the lead car.</outcome_measure>
      <outcome_measure>Driving Simulation Measuring Crash avoidance response time (in milliseconds)</outcome_measure>
      <outcome_measure>Driving Simulation Measuring Yellow Light Dilemma</outcome_measure>
      <outcome_measure>Driving Simulation Left Turn Gap Acceptance</outcome_measure>
      <outcome_measure>Performance-based tablet assessment: Critical Tracking</outcome_measure>
      <outcome_measure>Performance-based tablet assessment: Time estimation</outcome_measure>
      <outcome_measure>Performance-based tablet assessment: Balance</outcome_measure>
      <outcome_measure>Performance-based tablet assessment: Visual Spatial Learning Test</outcome_measure>
      <outcome_measure>Identification of Recent Cannabis Intake Using Whole Blood</outcome_measure>
      <outcome_measure>Assays for Oral Fluid Cannabidiol</outcome_measure>
      <outcome_measure>Assays for Oral Fluid Cannabinol</outcome_measure>
      <outcome_measure>Assays for Oral Fluid THC-glucuronide</outcome_measure>
      <outcome_measure>Assays of THC in Breath Specimens</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of California, San Diego</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>180</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Screening</study_design>
    </study_designs>
    <other_ids>
      <other_id>160641</other_id>
    </other_ids>
    <start_date>January 2017</start_date>
    <primary_completion_date>June 2019</primary_completion_date>
    <completion_date>June 2019</completion_date>
    <study_first_posted>July 29, 2016</study_first_posted>
    <last_update_posted>May 3, 2018</last_update_posted>
    <locations>
      <location>UC Center for Medicinal Cannabis Research, UC San Diego, San Diego, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02849587</url>
  </study>
  <study rank="8">
    <nct_id>NCT04325958</nct_id>
    <title>Age Differences in the Effects of Cannabis on Simulated Driving</title>
    <acronym>ADCUF</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cannabis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Cannabis</intervention>
      <intervention type="Drug">Placebos</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Standard deviation of lateral position</outcome_measure>
      <outcome_measure>Mean speed</outcome_measure>
      <outcome_measure>Standard deviation of speed</outcome_measure>
      <outcome_measure>Maximum speed</outcome_measure>
      <outcome_measure>Minimum time to collision</outcome_measure>
      <outcome_measure>Following distance</outcome_measure>
      <outcome_measure>Braking latency</outcome_measure>
      <outcome_measure>Number of collisions</outcome_measure>
      <outcome_measure>Blood concentration of delta-9-tetrahydrocannabinol (THC)</outcome_measure>
      <outcome_measure>Blood concentration of carboxy-tetrahydrocannabinol (THC-COOH)</outcome_measure>
      <outcome_measure>Blood concentration of 11-hydroxy-tetrahydrocannabinol (11-OH-THC)</outcome_measure>
      <outcome_measure>Systolic blood pressure</outcome_measure>
      <outcome_measure>Diastolic blood pressure</outcome_measure>
      <outcome_measure>Heart rate</outcome_measure>
      <outcome_measure>Temperature</outcome_measure>
      <outcome_measure>Respiration rate</outcome_measure>
      <outcome_measure>Visual Analog Scales such as 'I feel this effect', 'I like this drug effect', 'I feel the good effects'</outcome_measure>
      <outcome_measure>Digit Symbol Substitution Test</outcome_measure>
      <outcome_measure>Verbal Free Recall Task</outcome_measure>
      <outcome_measure>Useful Field of View Test</outcome_measure>
      <outcome_measure>Grooved Pegboard Test</outcome_measure>
      <outcome_measure>Simple and Choice Reaction Time Tasks</outcome_measure>
      <outcome_measure>Vienna Risk-Taking Test</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre for Addiction and Mental Health</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>19 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>128</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <other_ids>
      <other_id>048/2019</other_id>
    </other_ids>
    <start_date>September 2020</start_date>
    <primary_completion_date>September 2024</primary_completion_date>
    <completion_date>September 2024</completion_date>
    <study_first_posted>March 30, 2020</study_first_posted>
    <last_update_posted>April 3, 2020</last_update_posted>
    <locations>
      <location>Centre for Addiction and Mental Health, Toronto, Ontario, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04325958</url>
  </study>
  <study rank="9">
    <nct_id>NCT04060602</nct_id>
    <title>Personalized Feedback Intervention to Reduce Risky Cannabis Use.</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cannabis Use</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Personalized Feedback</intervention>
      <intervention type="Behavioral">Education</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Cannabis Use in the last 30 days</outcome_measure>
      <outcome_measure>Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST, cannabis subscale)</outcome_measure>
      <outcome_measure>Perceptions of Cannabis Use by Peers in the past 3 months</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre for Addiction and Mental Health</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>99 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>747</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>143/2018</other_id>
    </other_ids>
    <start_date>September 3, 2019</start_date>
    <primary_completion_date>October 15, 2020</primary_completion_date>
    <completion_date>October 15, 2020</completion_date>
    <study_first_posted>August 19, 2019</study_first_posted>
    <last_update_posted>October 27, 2020</last_update_posted>
    <locations>
      <location>Centre for Addiction Mental Health, Toronto, Ontario, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04060602</url>
  </study>
  <study rank="10">
    <nct_id>NCT03845842</nct_id>
    <title>Using Implementation Intentions to Reduce Cannabis Use</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cannabis Use</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Volitional help sheet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Cannabis use reduction (amount)</outcome_measure>
      <outcome_measure>Cannabis use reduction (frequency)</outcome_measure>
      <outcome_measure>Self reported habit as measured by the automaticity subscale of the Self-Report Habit Index.</outcome_measure>
      <outcome_measure>Self reported action control as measured by the scale developed by Sniehotta et al (2011)</outcome_measure>
      <outcome_measure>Self reported craving as measured by items from the mood and physical symptoms scale (MPSS)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Manchester</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Investigator)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <other_ids>
      <other_id>2018 5701</other_id>
    </other_ids>
    <start_date>February 14, 2019</start_date>
    <primary_completion_date>May 31, 2019</primary_completion_date>
    <completion_date>May 31, 2019</completion_date>
    <study_first_posted>February 19, 2019</study_first_posted>
    <last_update_posted>February 19, 2019</last_update_posted>
    <locations>
      <location>The University of Manchester, Manchester, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03845842</url>
  </study>
</search_results>
